No Data
INNOVENT BIO: 2024 ANNUAL REPORT
Citi is bullish on the China Medical Health Sector, with AI empowerment driving Ping An Healthcare (01833) to become the preferred stock.
Citi is bullish on the Chinese Medical and health sector, with Ping An Health and others as preferred stocks.
Zhuhai International: The pharmaceutical industry in China is expected to continue the valuation recovery this year, with the market for Innovative Drugs likely to differentiate.
Zhao Yin International published a report indicating that, driven by positive factors such as the export Trade of Innovative Drugs, optimization of domestic procurement policies, the implementation of the Class B medical insurance catalog for Innovative Drugs, the revival of tenders for Medical Devices, and the recovery of domestic demand, the Pharmaceutical Industry is expected to continue experiencing valuation repair in 2025.
Hong Kong Stock Announcement Gold Mining | BYD Company (01211) reported a net income of 9.155 billion yuan in the first quarter, an increase of 100.38% year-on-year.
SIHUAN PHARM (00460): The facial filler (child's face needle) independently developed by Meiyan Space has obtained market approval from the National Medical Products Administration; GRANDPHARMA (00512): The early detection product for urological tumors has achieved its first commercial prescription in mainland China.
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
INNOVENT BIO (01801): The third-generation EGFR TKI targeted drug for lung cancer, Aotinib (Leratinib tablets), has been approved by the NMPA for first-line indications.
INNOVENT BIO (01801) announced the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (T...
